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Abstract The present study comprised sarcomeric genotyp-
ing of the three most commonly involved sarcomeric genes:
MYBPC3, MYH7, and TNNT2 in 192 unrelated Egyptian
hypertrophic cardiomyopathy (HCM) index patients. Muta-
tions were detected in 40 % of cases. Presence of positive
family history was significantly (p00.002) associated with a
higher genetic positive yield (49/78, 62.8 %). The majority of
the detected mutations in the three sarcomeric genes were
novel (40/62, 65 %) and mostly private (47/62, 77 %). Single
nucleotide substitution was the most frequently detected mu-
tation type (51/62, 82 %). Over three quarters of these sub-
stitutions (21/27, 78 %) involved CpG dinucleotide sites and
resulted from C>T or G>A transition in the three analyzed
genes, highlighting the significance of CpG high mutability
within the sarcomeric genes examined. This study could aid in
global comparative studies in different ethnic populations and
constitutes an important step in the evolution of the integrated
clinical, translational, and basic science HCM program.
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Background
Evaluation of genetic basis of inherited heart muscle disease is a
prerequisite for further population, phenotypic, andmechanistic
studies. Hypertrophic cardiomyopathy (HCM) is a model of
common genetic heart disease attracting the interest of cardiol-
ogists, geneticists, scientists, and the public. Public interest is
usually temporarily raised following the diagnosis of HCM as
the cause of sudden death of a young competitive athlete [1].
Different population studies reported the prevalence of HCM,
based on left ventricular (LV) wall thickness greater than
15 mm, as 1:500 (0.2 %) [2, 3]. However, this frequency
represents the tip of the iceberg and is probably an underesti-
mate since it represents only the clinically manifest HCM and
does not include the prehypertrophic stage represented by the
genotype-positive/phenotype-negative cases [4]. Based on the
reported prevalence in different populations, an estimate of at
least 160,000 individuals is expected to be affected with HCM
within the over 80 million population of Egypt [5].
Although the incidence of this disease appears to be
constant in different parts of the world, its phenotypic and
genetic features seem to be quite heterogeneous. Laboratory
genetic analysis undertaken over the past two decades have
detected several hundred mutations in genes encoding pro-
teins within and associated with the sarcomere [6–8].
Why various clinical manifestations are found among those
who share the same sarcomeric gene mutation remains un-
known [9]. Factors that account for this variability are only
beginning to unravel. Diversity of the causal genes and muta-
tions are partly responsible, but modifier genes and environ-
mental factors also play a role in the phenotypic expression of
HCM [10, 11]. Extensive and continuous research in different
populations with different genetic backgrounds is imperative
to understand the heterogeneity of this disease.
Mutation in any of the sarcomeric genes (MYBPC3,MYH7,
TNNT2, TPM1, TNNI3, MYL2, MYL3, ACTC, and TTN) is
usually identified in approximately half of the genetically
screened HCM index cases [12, 13]. However, the proportion
of detection of a pathogenic mutation is population-dependent
and the reported frequency ranged from >50 % in France [12]
and Italy [14] to <30 % in Sweden [15]. The three most
commonly involved sarcomeric genes in HCM as reported in
several populations in Europe and USA are myosin binding
protein C (MYBPC3), β-myosin heavy chain (MYH7), and
cardiac troponin T (TNNT2) [6, 16]. It is, therefore, reasonable
to consider screening of those three genes as a first line strategy
for molecular characterization of HCM patients in Egypt.
HCM diagnosis is usually delayed till complications devel-
op and is, therefore, considered among the neglected diseases
particularly in the developing world. Establishment of tertiary
centers, which provide state-of-the-art management, can high-
ly benefit these patients and allow establishment of clinical
registries for systematized research and better understanding
of the pathophysiology of this common genetic cardiovascular
disorder [1]. Establishing national programs is invaluable for
sharing disease knowledge and creating networks for optimiz-
ing HCM care and encouraging research, hence, the initiative
of establishing the BA HCM national program in Egypt aim-
ing for clinical and molecular characterization of HCM among
Egyptian patients through nationwide collaboration between
clinical satellites extending from Alexandria in the north to
Aswan in the south and all being linked to molecular genetics
laboratory hosted in the Bibliotheca Alexandrina premises.
Subjects and Methods
HCM Patient Population
The present study comprised sarcomeric (MYBPC3, MYH7,
and TNNT2) genotyping of 199 consecutive unrelated HCM
index patients recruited from the different geographic
regions of Egypt from July 2007 to June 2010 following
standard clinical evaluation by 2D echocardiography at the
satellite HCM clinics in Alexandria Faculty of Medicine,
Cairo Faculty of Medicine, National Heart Institute, and
Aswan Heart Center. The study was approved by the Alex-
andria Faculty of Medicine and Aswan Heart Center Re-
search ethics committees and informed written consent was
obtained from all patients following provision of pretesting
genetic counseling. HCM patients' clinical assessment and
genetic testing in the BA HCM study is undertaken through
a multidisciplinary approach involving genetics and cardi-
ology specialties as illustrated in Fig. 1.
The diagnosis of HCM was based on the two-dimensional
echocardiographic evidence of a hypertrophied, nondilated
HCM proband recruited in BA HCM study  
Fig. 1 Multidisciplinary approach involving genetics and cardiology in
management of HCM patients and their families in BA HCM program
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left ventricle (wall thickness≥15 mm) in the absence of any
other cardiac or systemic disease, including hypertension,
capable of producing the magnitude of hypertrophy evident.
The basic clinical and echocardiographic data was extracted
from available patient clinical records and genotyping was
undertaken blinded of patient clinical data. Detailed clinical
characterization of the current patient cohort is beyond the
scope of the current manuscript.
At least three generations of family pedigrees were con-
structed and cases were considered familial if there was a
positive family history of clinically diagnosed HCM or con-
sidered suggestive to be familial through presence of family
history of sudden cardiac death particularly if occurring at a
young age <40 years. Also, history of consanguinity was
always reported whenever present.
Molecular Genetic Analysis
Genomic DNAwas extracted from 4 to 6 ml of blood samples
donated from index HCM patients following written informed
consent and was amplified for the coding exons and flanking
intronic sequences of the three candidate sarcomeric genes:
MYH7 (NM_000257.2, 38 coding exons were analyzed: third
to 40th exons), MYBPC3 (NM_000256.3, 34 exons, first to
34th), and TNNT2 (NM_001001430.1, 16 exons, second to
17th). Primers sequences are available upon request.
Initial screening for mutations was undertaken using hetero-
duplex analysis by denaturing high-performance liquid chroma-
tography (DHPLC) using WAVE™ DNA Fragment Analysis
System. The conditions for DHPLC were developed on the
basis of amplicon-specific melting profiles predicted by the
Navigator software (Transgenomics, San Jose, CA, USA).
Two melting temperatures were analyzed for most of the exons
(54/88061 %) and a single temperature for 24 (26 %) and three
temperatures for 12 (13 %) amplicons. DHPLC sensitivity is
reported as 95 % as compared to each amplicon-automatic
sequencing [14].
Samples showing a variant profile (different from the wild
pattern) for any of the amplicons were subjected to bidirectional
sequencing using automated dye terminator cycle–capillary
electrophoresis (ABI 3500 Applied Biosystems, Foster City,
CA, USA) to determine the nature of the sequence change
(Fig. 2).
Pathogenicity of variants detected in the present study
was dependent on being previously reported to relate to
HCM. For novel variants, pathogenicity was evaluated on
several criteria including: absence in at least 200 unrelated
chromosomes from age- and sex-matched healthy controls
of the same ethnicity, cosegregation of the mutation with the
disease phenotype in the proband's family, and the conser-
vation of the mutated residue in different species in addition
to pathogenicity prediction using in silico biosoftware
analysis.
In Silico Analysis of Variants Using Alamut-2.0.2
Biosoftware
Predicting Damaging Effect of Amino Acid Substitution
Prediction of novel missense mutation pathogenicity was
undertaken through analyzing the physicochemical proper-
ties of the substituted amino acid relative to the wild one
through licensed online predictive Alamut-2 Biosoftware
(http://www.interactive-biosoftware.com).
Splice Site Error Predictions
Substitutions within introns flanking the coding exons of the
three sarcomeric genes (MYBPC3, MYH7, and TNNT2) were
firstly excluded as being reported as single nucleotide poly-
morphisms (SNPs) and were also tested in at least 200 alleles
of healthy subjects (Appendix). The variants that were not
detected in controls were subjected to in silico analysis for
prediction of possible splice site alteration using online pro-
grams such as splicesitefinder (SSF) and Human Splicing
Finder splice site analysis (HSF). The variants with a pre-
dicted possible splice site effect were considered as “variants
of uncertain significance” and were checked whenever possi-
ble for cosegregation within the family with HCM phenotype
to determine their potential for pathogenicity.
Results
Study Population
One hundred and ninety-nine patients were consecutively
enrolled in the present study. The patient cohort comprised:
192 clinically diagnosed HCM patients, a single patient had
LV noncompaction cardiomyopathy without hypertrophy
(P76), and six patients were clinically suspected as HCM
phenocopies: five patients were suspected to be infiltrative
due to storage disease based on symmetrical hypertrophy
and highly reflective myocardium (data not shown) and/or
presence of history of parental consanguinity and presence
of horizontal transmission pattern and one patient was sus-
pected to have mitochondrial cardiomyopathy due to asso-
ciated bilateral optic neuritis. Another patient was clinically
suspected of LEOPARD syndrome due to associated pig-
mented cutaneous lesions. The fact that no further biochem-
ical analysis was undertaken at the time of sarcomeric
genetic testing, it was decided to include all enrolled
patients to the three sarcomeric gene analyses. All suspected
HCM phenocopies were negative for mutations in the three
sarcomeric genes analyzed in the present study and were,
therefore, excluded in further frequency estimation and sta-
tistical analysis.
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Demographics of the 192 Egyptian HCM patients are
shown in Table 1. Males were twice as common as females
(68 % vs. 32 %), patients' age of presentation ranged from 2
to 70 years, and 53 % of the cases presented at or below
40 years. Cases were considered familial in the presence of
positive family history of a diagnosis of HCM detected in 60
cases (60/192, 31 %) or presence of familial incidence of
sudden cardiac death (18/192, 9 %). Sarcomeric mutations
were detected in 62.8 % (49/78) of familial HCM cases.
Summary of the basic parameters measured by 2D echocar-
diography and wave Doppler are shown in Table 1.
Molecular Analysis
Prevalence of Mutations in MYBPC3, MYH7, and TNNT2
Sarcomeric Genes
Seventy-seven index HCM patients harbored one or more
mutation in any of the three analyzed sarcomeric genes (77/
192, 40 %) (Tables 2 and 3). Among the genopositive
patients, the highest frequency of mutations was detected
in MYBPC3 (48/77, ~60 %), followed by MYH7 (24/77,
~30 %), and the least involved was TNNT2 (8/77, ~10 %).
Details of mutations detected are shown in Table 2 and
potential splice site mutations predicted by in silico analysis
are shown in (Table 3).
Missense mutation was the most commonly encountered
mutation type in the three sarcomeric genes. There were 62
individual mutations detected in any of the three sarcomeric
genes in the present cohort, the majority of which (47/62,
77 %) were detected in single index patient (i.e., private)
(Tables 2 and 3). Most of the mutations detected in the
studied cohort were novel (40/62, 65 %) and were not
detected in 200 alleles of age-, sex-, and ethnically matched
control series nor in the 1000 Exome Variant Server (EVS)
[36]. Three missense mutations detected in our HCM
patients (Ala177His, Arg1138 in MYBPC3, and
Arg1662His in MYH7) were found in the EVS; however,
they were reported at low allele frequencies (0.003, 0.0002,
and 0.00008, respectively). Additionally, seven missense
mutations previously reported as pathogenic in relevance
to HCM and also found in the present cohort (Ala216Thr,
Clu441Lys, Gly507Arg, Glu619Lys, Val771Met,
Glu1179Lys in MYBPC3, and Ala797Thr in MYH7) were
also reported in the EVS. This finding should be interpreted
with caution. While on the one hand, these variants might be
regarded as rare polymorphic nonpathogenic variants, on the
other hand, it could still have a pathogenic and/or modifier
effect in a disease with the heterogeneous nature of HCM
having later age of onset and reduced penetrance especially
when considering controls not thoroughly evaluated by
electrocardiogram (ECG) and echo. Further screening in a
Fig. 2 Strategy of genetic
analysis in BA HCM study
through initial screening with
DHPLC (WAVE™
Transgenomics) followed by
bidirectional automated
sequencing of variant profile
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larger number of ethnic-matched controls with thorough
cardiologic evaluation is warranted.
MYBPC3 Mutation Spectrum MYBPC3 was the most com-
monly involved in the present cohort (47 patients were
MYBPC3-genopositive, 47/192, 24 %). Thirty-five individ-
ual mutations were detected inMYBPC3, 18 mutations were
missense, seven were nonsense, eight were deletion muta-
tion of which six caused frameshift effect resulting in pre-
mature stop codon and two mutations caused in-frame
deletion of a single or more amino acids (Table 2).
In addition, two mutations were detected in introns 32
and 7, namely, c.3627+2delT (PU2) and c.821+3G>T
(PU1), respectively (Table 3). These variants are likely to
result in splice site error since both were absent in 200
chromosomes of unrelated healthy subjects and the former
is affecting the conserved 5′ donor splice site dinucleotide
GT of intron 32 and the latter (c.821+3G>T) was predicted
to result in splice error by in silico modeling and was found
to cosegregate with the HCM phenotype in a HCM family
member (PU1′a), thus, in favor of its potential pathogenic-
ity. In further support of this speculation is the fact that the
index patient PU1 was double heterozygote and also carried
missense mutation in MYH7 exon39 (p.Arg1662His) that
did not cosegregate in the affected family member (PU1′a)
(Fig. 3).
Twenty-five mutations (25/35, 71 %) of MYBPC3 were
private (i.e., reported in a single index patient) and ten
mutations were found in more than one patient: five muta-
tions were detected in two unrelated index patients, three
mutations were individually found in three unrelated
patients, and two mutations were detected in four unrelated
index patients suggesting a possible founder effect
(Table 2).
A single patient had noncompaction LV cardiomyopathy
without hypertrophy (P76) and carried missense mutation in
MYBPC3 (p.Glu619Lys) that was also detected in another
HCM patient in the present cohort and was previously
reported in association with HCM [21].
Table 1 Demographic data of the Egyptian hypertrophic cardiomyop-
athy patients
Feature (%) Nc or mean±SD
Gender
Male 68 % (130/192)
Female 32 % (62/192)
Age at diagnosis (in years) 36.8±16.80
Median (range) 38 (2–70)
≤40 years 53.1 % (102/192)
>40 years 45.8 % (88/192)
Family history 40.6 % (78/192)
Of diagnosed HCM 31.2 % (60/192)
Of sudden death 9.4 % (18/192)
+vea for sarcomeric mutation/
+ve family history
62.8 % (49/78)
Clinical presentation
Shortness of breath (NYHA)
I 22.6 % (51/192)
II 44.3 % (85/192)
III 22.9 % (44/192)
IV 6.2 % (12/192)
Chest pain 65.6 % (126/192)
Palpitation 66.1 % (127/192)
Syncope/presyncope 52.6 % (101/192)
Baseline echocardiographic parameters
Left atrium (mm) 44.7±9.3
LV outflow gradient≥30 mmHg 56.7 % (103/185)
Max. LV thickness (mm) 25.3±19.7
<30 mm 80.9 % (149/184)
≥30 mm 19.0 % (35/184)
Symmetrical hypertrophy 1.1 % (2/185)
Asymmetrical hypertrophy 98.9 % (183/185)
Site of maximum thickness:
Isolated septal hypertrophy 56.2 % (104/185)
Septal and posterior wall
hypertrophy
28.7 % (53/185)
Apical hypertrophy 2.7 % (5/185)
LV end-diastolic dimension (mm) 44.2±8.3
LV end-systolic dimension (mm) 26.6±6.5
Mitral regurgitation (MR): 68 % (125/185)
Trivial/mild MR 47 % (87/185)
Moderate MR 14 % (26/185)
Severe MR 7 % (12/185)
SAM 62 % (114/185)
Major cardiac eventsb
Sudden cardiac death 2 % (2/100)
Previous cardiac arrest 2 % (2/100)
Heart failure 3 % (3/100)
Stroke 1 % (2/100)
Interventions for obstruction/symptoms
Alcohol septal ablation 1 % (2/192)
Surgical septal myectomy 27 % (52/192)
Table 1 (continued)
Feature (%) Nc or mean±SD
ICD 1 % (2/192)
Pacemaker 3 % (5/192)
ICD implantable cardioverter-defibrillator, LV left ventricular, NYHA
New York Heart Association, SAM systolic anterior motion
a +ve: positive
b Total number includes cases with available follow-up data
c Total number varies according to available clinical data of parameters
assessed
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MYH7 Mutation Spectrum Twenty-one individual muta-
tions of MYH7 were detected in 24 unrelated index patients
(24/192, 12.5 %). Of these, 19 were missense, two were
deletion mutations, one of which was in-frame deletion
resulting in deletion of a single amino acid (Lys847del)
and one resulted in frameshift mutation (p.Ser1924A-
lafsX9). All mutations were private except two that were
detected in more than one index patient, Arg719Gln was
detected in two and Ser1924AlafsX9 was detected in three
unrelated index patients (Table 2).
TNNT2 Mutation Spectrum TNNT2 was the least commonly
involved gene in our cohort (8/192, 4 %). Six missense
mutations were detected in TNNT2, most of which were
novel (4/6, 67 %) (Table 2). In addition, two missense
mutations involving Arg92 codon (Arg92Trp and
Arg92Gln) [34, 35] were detected in one and two patients,
respectively.
Occurrence of Double Hits Seven patients in the present
cohort (7/192, 4 %) carried double hit mutations in one or
more of the analyzed sarcomeric genes. Five were compound
heterozygotes within MYBPC3 (P62, PA53, P48, P4, and
P92). Two patients were double heterozygotes (PA26 and
PU1): PA26 carried missense mutation in MYBPC3
(p.Val771Met) and another in MYH7 (Leu267Val) and PU1
had substitutionmutation within intron 7 ofMYBPC3 (c.821+
3G>T) with a predictive splice error effect and a missense
mutation in MYH7 (Arg1662His), and only the intronic vari-
ant was cosegregating in an affected family member (PU1′).
Table 3 Possible splice site error associated with novel intronic substitution
Gene Intron Mutation name according to
coding DNA level (cDNA)
No. of patients
(IDs)
Cosegregation Detection in Egyptian controls
(200 alleles) or reported in EVSa
(allele freq) 1 0 present 0 0 Absent
MYBPC3 3 c.407−7C>A 2 (P14, P16) Absent (P14′a) 0
MYBPC3 7 c.821+3G>T 1 (PU1) Yes (PU1′A) 0
MYBPC3 16 c.1458−7C>A 1 (P89) TBP* 0
MYBPC3 16 c.1458−17C>G 1 (P17) TBP* 0
MYBPC3 22 c.2149−8C>T 1 (P100) TBP* 0
MYBPC3 32 c.3627+2del 1 (PU2) NT 0
TNNT2 14 c.690−4G>T 1 (P32) TBP* 1 (0.0002)a
TNNT2 15 c.781−48_64del 1 (PA78) TBP* 0
MYBPC3 NM_000256.3,MYH7 NM_000257.2, TNNT2 NM_001001430.1, NT not tested, TBP* To Be Pursued by family clinical screening to test
cosegregation in affected family members
a Allele frequency obtained from Exome Variant Server (EVS) of Exome Sequencing Project (ESP): http://evs.gs.washington.edu/EVS/) [36].
Mutations in bold were reported in EVS
Fig. 3 Bidirectional automated
sequencing of MYBPC3 exon7
and MYH7 exon35 and flanking
intronic sequences in index
patient PU1 and screening of an
affected brother (PU1′a)
showing cosegregation of
MYBPC3 intron 7 substitution
mutation: c.821+3G>T with
potential splice effect as
predicted by in silico tools and
not MYH7 missense variant
(Arg1662His) indicating likely
pathogenicity of the MYBPC3
intronic variant
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Possible Founder Effect Two novel MYBPC3 mutations
showed a particular geographic distribution in Egypt indicating
a possibility for a founder effect. The frameshift mutation
p.Trp1098X in exon30 was detected in three unrelated patients
from the northwest Mediterranean coast in Alexandria gover-
norate inhabited by Bedouin tribes. Another frameshift muta-
tion, p.Asp506ThrfsX7 in exon15, was detected in three
unrelated index patients from the Nile River Delta region in
Damietta governorate.
Interestingly, two unrelated index patients (P4 and P92) were
compound heterozygotes for two mutations (p.Glu832Gly and
p.Arg845Pro) within exons 25 and 26 ofMYBPC3 gene. These
two mutations are likely to be in cis as they were cosegregating
in an affected family member of P4. This may also suggest a
founder effect due to the fact that both mutations were cosegre-
gating in unrelated index patients.
Bioinformatic Analysis of Substitution Mutations for Possi-
ble Splice Error Effect All novel variants detected in
intronic sequences flanking the coding exons of the three
sarcomeric genes were initially checked through online ge-
nomic SNP database (http://snpper.chip.org/). Those which
were not determined as a SNP were subjected to in silico
analysis for prediction of splice error effect (Table 3).
Apart from the single variant that involved the conserved
donor splice site of intron 32 of MYBPC3 (c.3627+2delT)
in PU2 and was considered as pathogenic, nine intronic
novel variants were predicted by in silico analysis to cause
a splice site error. Three were determined as not likely to be
pathogenic since two of which were detected in the Egyp-
tian control series [c.2149-5C>T(P87) in intron 22 of
MYBPC3 (detected in 1 % of the controls) and c.3337-
3dup (PA2) in intron 27 of MYH7 (was found in 16 % of
the controls series)], and one variant detected in MYBPC3
intron 3 (c.407-7C>A) was not cosegregating with HCM
phenotype in an affected relative of index P14.
Cosegregation provides a direct method for excluding that a
variant is the sole cause of disease within a family. It was,
therefore, always sought whenever possible. In the present
study, c.821+3G>T in intron 7 ofMYBPC3was cosegregating
with HCM phenotype in a family member of index PU1, thus,
providing evidence for potential pathogenicity, especially that
the other mutation found in PU1 inMYH7 (p.Arg1662His) was
not cosegregating in the affected relative (Fig. 3). The missense
variant (p.Arg1662His in MYH7) was reported in the EVS
with a very low allele frequency: 0.00008 (Table 2).
Three intronic substitutions in MYBPC3 (c.1458-7C>A,
c.1458-17C>G, and c.2149-8C>T) and two in TNNT2
(c.690-4G>T and c.781-48_64del) were classified as variants
of undetermined clinical significance since they were predicted
by in silico analysis to result in splice error (Table 3) and were
absent in 200 chromosomes of healthy subjects. It is worth
mentioning that variant c. 690-4G>Twas reported in EVS at an
allele frequency of 0.0002 and that cosegregationwas not tested
till writing of the current manuscript and should be pursued
prior to considering the potential pathogenicity of this variant. It
is worth mentioning that these in silico predictions of splice
errors should be validated by ribonucleic acid (RNA) analysis.
In Silico Prediction of Novel Missense Mutation Pathogeni-
city The novel missense substitutions are initially excluded in
at least 200 chromosomes of matched healthy volunteers and
are also subjected to in silico bioinformatic analysis for pre-
diction of pathogenicity, which included several scoring sys-
tems (Table 4). The Grantham Difference, which depends on
the composition, polarity, and molecular volume of the wild
and substituted amino acid, shows that the higher the score,
the less tolerated the amino acid substitution. Align GVGD
combines Grantham difference of amino acids and protein mul-
tiple sequence alignments to predict whether the missense sub-
stitution falls in a spectrum from enriched deleterious to
enriched neutral (http://agvgd.iarc.fr/). Sorting Intolerant from
Tolerant (SIFT) depends on the degree of conservation of amino
acid residues in sequence alignments derived from closely relat-
ed sequences in different species (http://sift.jcvi.org). Polymor-
phism Phenotyping (Polyphen-2) predicts possible impact of an
amino acid substitution on the structure and function of a human
protein using physical and comparative considerations (http://
genetics.bwh.harvarad.edu/pph2/).
The likelihood of pathogenicity of a novel missense variant
is analyzed according to output of the available bioinformatic
tools. At least two programs agreeing in predictive output is
used to determine pathogenicity. The concurrent occurrence of
novel variants of uncertain clinical significance in several un-
related families such as MYBPC3/Pro102Leu (in P19 and
PA69), MYBPC3/Glu832Gly and MYBPC3/Arg845Pro (in P4
and P92), and TNNT2/Asn269Lys (in P47 and PA66) in addi-
tion to their absence in our control series and in the 1000 exome
project (EVS) [36] favored their pathogenic potential.
Uncertain and likely pathogenic variants were always
checked for cosegregation whenever possible. Interestingly,
the MYH7/Arg1662His detected in a single index patient
(PU1) detected as a second hit was determined by in silico
analysis as a benign/tolerated variant and was not cosegre-
gating with HCM phenotype in an affected family member,
and its being reported in EVS (with an allele frequency of
0.00008) are in favor of its less likelihood of a direct role in
pathogenicity of HCM and may have a modifier effect. The
de novo concurrence of the double in cis variants of
MYBPC3 exon25 (Glu832Gly) and exon26 (Arg845Pro) in
two families (P4&P92) were found to cosegregate in the
affected family member of P4 favoring the pathogenic effect
of one or either of them.
Mutations Involving CpG Dincleotides All substitution
mutations were analyzed in context of the reference
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GenBank sequence of the three sarcomeric genes. It was
observed that over half (27/51, 53 %) of all substitution
mutations resulting in missense and nonsense effect oc-
curred in CpG dinucleotides [60 % in MYBPC3 (15/25),
40 % inMYH7 (8/20), and 66.6 % in TNNT2 (4/6)] (Table 2).
In relation to mode of nucleotide substitution in the CpG
site, it was observed that the most commonly encountered
types were the G>A and C>T transitions, 55.6 % (15/27)
and 22.2 % (6/27), respectively. On the other hand, the C>
A, G>C, and G>T transversion types were detected less
frequently, [11.1 % (3/27), 7.4 % (2/27), and 3.7 % (1/27),
respectively] (Table 5). The fact that over three quarters of
these single nucleotide substitutions involving the CpG sites
(21/27, 78 %) resulted from C>T or G>A transition in the
three genes [73.3 %(11/15) in MYBPC3, 100 % (8/8) in
MYH7, and 50 % (2/4) in TNNT2] highlights the signifi-
cance of CpG high mutability resulting from deamination of
5-methylcytosine to thymine within the CpG sites in sarco-
meric genes causing HCM among Egyptian patients.
Table 4 Bioinformatic analysis of novel missense mutations associated with hypertrophic cardiomyopathy among Egyptian patients
Gene/mutation
in protein level
Grantham
difference
(0–225)
SIFTb D 0 deleterious
(score<0.05) T 0 tolerated
(score>0.05)
Align GVGD
classc
Polyphen-2
(score)d
Likelihood of
pathogenicitye
MYBPC3/Val94Ala 64 D (0.01) C25 Probably damaging (0.999) Likely
MYBPC3/Pro102Leua 98 D (0.04) C0 Benign (0.008) Pathogenic
MYBPC3/Arg177His 29 D (0.01) C0 Possibly damaging (0.889) Likely
MYBPC3/Glu319Ala 107 T (0.53) C0 Benign (0.014) Uncertain
MYBPC3/Thr445Met 81 D (0.00) C65 Probably damaging (1.000) Likely
MYBPC3/Arg470Pro 103 D (0.00) C65 Probably damaging (0.999) Likely
MYBPC3/Asn515Asp 23 D (0.00) C15 Benign (0.040) Uncertain
MYBPC3/Glu832Glya 98 D (0.00) C65 Probably damaging (1.000) Pathogenic
MYBPC3/Arg845Proa 103 D (0.00) C65 Probably damaging (1.000) Pathogenic
MYBPC3/Leu993Phe 22 D (0.03) C0 Probably damaging (0.983) Likely
MYBPC3/Arg1138Cys 180 D (0.00) C65 Probably damaging (1.000) Likely
MYH7/Glu170Lys 56 D (0.00) C0 Probably damaging (0.996) Likely
MYH7/Leu267Val 32 D (0.00) C0 Benign (0.011) Uncertain
MYH7/Asp309Asn 23 D (0.00) C0 Probably damaging (0.963) Uncertain
MYH7/Glu379Lys 56 D (0.00) C0 Benign (0.315) Uncertain
MYH7/Asp394Glu 45 D (0.00) C0 Probably damaging (1.000) Likely
MYH7/Asn471Ser 46 D (0.00) C45 Benign (0.019) Likely
MYH7/Gln498Arg 43 D (0.00) C35 Benign (0.370) Likely
MYH7/Gly716Ala 60 D (0.00) C55 Possibly damaging (0.948) Likely
MYH7/Arg819Gln 43 D (0.00) C35 Probably damaging (1.000) Likely
MYH7/Glu1056Asp 45 D (0.00) C0 Probably damaging (0.997) Likely
MYH7/Arg1662His 29 D (0.00) C0 Benign (0.001) Uncertain
TNNT2/Asn152Tyr 143 T (0.06) C0 Possibly damaging (0.951) Likely
TNNT2/Asn272Asp 23 T (0.32) C0 Possibly damaging (0.820) Uncertain
TNNT2/Asn269Lysa 94 T (1.00) C0 Benign (0.028) Pathogenic
TNNT2/Arg288Leu 102 T (1.00) C0 Probably damaging (0.972) Uncertain
a De novo concurrent with HCM in more than a single family
b Sorting intolerant from tolerant prediction
c Scores include GV00 (invariable), 0<GV<62 0 variable conservative, GV>62 0 variable nonconservative
d Polymorphism phenotyping
e Likelihood of pathogenicity based on in silico analysis and de novo concurrence of variant in unrelated HCM cases
Table 5 Frequency of
different substitution
modes within CpG in
the present HCM cohort
Mode of substitution
in CpG
Frequency in
present cohort
G>A 55.6 % (15/27)
C>T 22.2 % (6/27)
C>A 11.1 % (3/27)
C>G 0 % (0/27)
G>C 7.4 % (2/27)
G>T 3.7 % (1/27 )
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Influence of Genetic Mutation on Clinical Phenotype
The clinical parameters comprised of presence of familial
history of HCM and/or occurrence of sudden cardiac death
(SCD) in the family, age of presentation at a cutoff ≤40 years,
and presence/absence of LV outflow obstruction and maxi-
mum LV wall thickness being categorized into two groups
(≤30 mm and >30 mm) were assessed in relevance to detec-
tion of positive mutation. It was observed that the positive
genetic yield in any of the three sarcomeric genes was signif-
icantly associated with presence of family history of HCM
and/or occurrence of SCD (p00.002) and with young age of
presentation at ≤40 years (p00.004) (Fig. 4). There was an
observed trend of presence of mutation in association with
increased LV maximum thickness (>30 mm), but this did not
reach significance (p00.08). There was no statistically signif-
icant difference in the LV thickness among the genotype-
positive cases of the three sarcomeric genes (using analysis
of variance (ANOVA) test, p00.36, Table 6).
There was also no statistically significant difference ob-
served between the genopositive and genonegative patients
with respect to initial clinical presentation with regards to
severe degree of dyspnea (NYHA class III/IV), chest pain,
and syncope (24 vs. 29 p00.39, 51 vs. 75 p00.95, and 19
vs. 22 p00.37, respectively). The overall prevalence of
atrial fibrillation was not significantly different between
both groups (p00.80). It was observed that prior cardiac
arrests in this cohort (Table 1) occurred only in genopositive
patients. As for incidence of other events as cardiac death
and stroke, they were similar between the two groups. It is
difficult at present to assess a correlation between adverse
major cardiac events and genetic status due to the relatively
short follow-up duration (median 38.8 months, range 30–
49 months). Assessment of genotype–phenotype correlation
is still under investigation.
Fig. 4 Univariate analysis of
clinical parameters as predictors
of positive sarcomeric genetic
yield in Egyptian HCM patients
using chi-square test (MedCalc-
version 12.2.1) *Statistically
significant association at p val-
ue <0.05
Table 6 Comparison of LV maximum thickness among the genotype
positive cases of the three sarcomeric genes
MYBPC3 MYH7 TNNT2 Double_hits
Mean (SD) 2.59 (0.61) 2.57 (0.70) 2.17 (0.42) 2.39 (0.88)
ANOVA 1.08
P value 0.36
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Discussion
This study represents the first report of comprehensive
screening of MYBPC3, MYH7, and TNNT2 in 192 Egyptian
HCM patients, of whom 78 were familial (40.6 %). Initial
screening of commonly involved sarcomeric genes is a
justifiable first line approach of HCM genotype analysis
[12, 14]. The frequency of positive sarcomeric genotyping
detected among the Egyptian HCM index patients (40 %) is
comparable to the frequency reported by Van Driest et al. in
an earlier study [6], in which eight sarcomeric genes were
analyzed in 389 HCM patients (38 % were genopositive).
Also, recently, Curila et al. reported a similar frequency
(40 %) analyzing four sarcomeric genes (MYBPC3, MYH7,
TNNT2, and TNNI3) in 100 HCM patient [37]. However, the
proportion of genetic yield varied among different popula-
tion cohorts and ranged from >50 % in France and Italy [12,
14] to <30 % in Sweden [15]. This variation in frequency of
positive genetic yield may probably relate to the proportion
of familial cases included in the different cohorts. The
positive sarcomeric genetic yield detected in the present
cohort was significantly associated with presence of family
history of HCM and/or occurrence of sudden cardiac death
(p00.002) and with young age of presentation (p00.004).
MYBPC3 was the most commonly involved sarcomeric
gene (24 %) and was twice as common as MYH7 (12 %), and
TNNT2was the least commonly involved in the present cohort.
MYBPC3 and MYH7 accounted for 87 % of all genotype-
positive patients. A similar genotype pattern was also observed
in several European HCM cohorts [12, 14, 25, 37].
HCM is considered a highly heterogeneous disease not
just at the phenotype but also showing marked genetic
heterogeneity. This is reflected as a high frequency of novel
mutations reported in different population studies [6, 12, 14]
limiting the possibility of screening for specific genes or
particular mutations in research and clinical practice. How-
ever, different ethnic cohorts including the present study
revealed repetitive particular genotype association that may
relate to a founder effect [14, 38–40], highlighting the
importance of genetic screening in different populations.
A high proportion of the mutations detected in the present
cohort were novel (65 %) and assessment of their potential
pathogenicity was undertaken based on the practice guidelines
for interpretation of unclassified variants in clinical molecular
genetics, and the overall conclusion was based on more than a
single line of evidence [41]. Accordingly, novel variants in the
present study were classified as: uncertain, likely pathogenic,
and pathogenic. This molecular stratification of variants was
always considered in genetic counseling. An example is of a
family pedigree with a novel variant (MYH7: Asp309Asn) in
index patient (PA8). This novel variant, according to in silico
bioinformatic analysis, was predicted as probably damaging by
PolyPhen-2 (score 0.963) and was considered as unlikely to be
damaging by other in silico tools (Table 4). It has not been
detected in 200 chromosomes of matched healthy controls and
was tested for cosegregation within the family. The mutation
was detected in two sibs who were phenonegative by standard
echocardiographic screening. Thus, confirmation of pathoge-
nicity is not possible at the current stage; however, follow-up of
the phenonegative sibs is warranted since the mutation patho-
genicity is uncertain and reduced penetrance is a possibility.
Single nucleotide substitution was the most commonly
encountered mutation type (51/62, 82 %). These substitutions
were analyzed in context of the reference GenBank sequence
of the three sarcomeric genes to determine whether deamina-
tion of five methyl cytosine and transition to thymine repre-
sented a common cause of mutagenesis in sense or antisense
DNA strands of sarcomeric genes in our HCM cohort
[42–45]. It was found that C>T and G>A transitions consti-
tuted 78 % (21/27) of the substitutions occurring within the
CpG dinucleotides in the present cohort (as shown in Table 5).
This is in agreement with the frequency of C>T and G>A
transition reported by Meures and Mealey [46] in substitution
mutations found in HCM in the literature (Table 7).
This observation probably explains the theory behind
some mutation recurrence in several HCM cohorts of dif-
ferent ethnicity: such as the functionally characterized [47]
Arg92codon mutation of TNNT2 reported in several studies
[34, 35, 48], the E258K mutation of MYBPC3 reported with
a founder effect among the Italian population [14], and the
Ala797Thr reported with a possible founder effect in South
Africa [49]. All such missense mutations involve CpG sites
and are, therefore, likely to be hypermutable spots and
hence, were also detected in other studies including the
present. The hypothesis of considering codon Arg92 as a
putative hot spot with high mutation rate rather than recur-
rence among different populations due to a common founder
effect was earlier proposed by Forissier et al. [48]. It is
worth mentioning that other reported founder mutation
resulting from deletion or insertion such as the Dutch
2373insG (Q791fs) in MYBPC3 [50] was not detected in
Table 7 Frequency of different substitution modes within CpG in the
present cohort in comparison to previously reported mutations in the 3
analyzed sarcomeric genes
Mode of substitution
in CpG
Present study Previously reported
CpG substitutionsa
G>A 15/27055.6 % 113/251045 %
C>T 6/27022.2 % 56/251022.3 %
C>A 3/27011.1 % 13/25105.2 %
C>G 0/2700 % 18/25107.2 %
G>C 2/2707.4 % 30/251012.0 %
G>T 1/2703.7 % 21/25108.4 %
a [46]
76 J. of Cardiovasc. Trans. Res. (2013) 6:65–80
the current study. The high mutability at the CpG sites
within the sarcomeric genes probably explains also the high
frequency of novel mutations detected in different studies
[12, 14, 25, 37] including that observed in the present study
(65 %).
Conclusion and Future Directions
This study is the first to provide genetic data of HCM
among Egyptians. Positive genotype was detected in 40 %
of our cohort. Expanding the genetic screening analysis
through use of next-generation sequencing technology to
enable simultaneous analysis of a broad panel of inherited
cardiovascular disease-related genes is expected to increase
the genetic-positive yield. Molecular characterization of
HCM in different ethnic populations with different genetic
backgrounds will aid in global comparative studies helping
to understand the pathophysiology and heterogeneity of
HCM. The true value of these studies lies in their translation
to the clinical setting and their utilization towards improved
HCM diagnosis, prognosis, and treatment [51, 52]. It is
anticipated that the molecular screening of HCM patients
and their family members is likely to improve the manage-
ment of HCM in Egypt.
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Gene Ex./In. Mutation name
(c.DNA)
Amino acid
change
MAF/minor allele count in EVS dbSNP
Egyptian European
American
African
American
MYBPC3 Ex.4 c.472G>A V158M T=0.06/12 T=0.0864/718 T=0.0171/69 rs3729986
MYBPC3 In.5 c.506-12delC NA Del.=0.23/46 – – rs11570050
MYBPC3 In.11 c.927-46G>C NA G=0.005/1 G=0.0001/1 G=0.016/62 rs73451796
MYBPC3 In.13 c.1223+29G>A NA T=0.01/2 T=0.1174/958 T=0.0366/ 141 rs11570078
MYBPC3 In.14 c.1227-19C>A NA T=0.02/4 – – –
MYBPC3 In.14 c.1227-32T>A NA T=0.005/1 – – –
MYBPC3 In.16 c.1458-26C>G NA C=0.005/1 C=0.0/0 C=0.0112/47 rs11570081
MYBPC3 In.22 c.2149-5C>T NA A=0.005/1 – – rs36211722
MYBPC3 In.22 2148+39T>C NA G=0.005/1 – –
MYBPC3 In.23 c.2308+18C>T NA A=0.015/3 – – –
MYBPC3 In.26 c.2737+12C>T NA A=0.025/5 A=0.0257/206 A=0.0513/192 rs3729936
MYH7 In.11 c.999+44T>C NA G=0.005/1 G=0.0886/762 G=0.4017/1770 rs3729810
MYH7 In.16 c.1888+23G>A NA T=0.02/4 – – –
MYH7 In.20 c.2287-43C>T NA A=0.005/1 A=0.0001/1 A=0.0/0 –
MYH7 In.23 c.2923-18G>A NA T=0.02/4 T=0.0009/8 T=0.1512/666 rs7157087
MYH7 In.27 c.3337-3dup NA Dup.=0.08/16 – – rs45504498
MYH7 In.28 c.3853+27T>A NA T=0.01/2 T=0.3628/3120 T=0.6239/4406 rs2277475
MYH7 In.32 c.4520-3C>T NA A=0.005/1 – – –
MYH7 Ex.32 c.4472C>G S1491C C=0.005/1 C=0.0115/99 C=0.003/13 rs3729823
TNNT2 In.2 c.41+75C>G NA C=0.005/1 C=0.0/0 C=0.0275/38 rs10920185
TNNT2 In.2 c.41+86C>A NA T=0.005/1 – – –
Appendix
Table 8 Variants detected in Egyptian controls in comparison with European Americans and African Americans from Exome
Variant Server database
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